Know more now.

Discover a better way to help manage your immunotherapy treatment.

Every person’s cancer requires a unique management approach and personalized treatment. During treatment with immune-checkpoint inhibitors (ICIs), also known as immunotherapy you and your doctor want answers to critical questions as soon as possible. Signatera is a new blood test that is personalized to each person’s individual set of tumor mutations.

Signatera can tell you earlier than traditional tests whether small amounts of cancer are still in your body and if your cancer is likely to come back. Knowing this information earlier can help you have a more informed discussion with your doctor regarding your immunotherapy treatment and follow-up plans.

As I continue my battle with
cancer, I have learned that we must
be our own advocates and
work with our doctors as a team.

LUANN

patient

Discover our BESPOKE study of ctDNA-guided therapy for IO cancer management

Be a part of something truly groundbreaking. Join Natera’s BESPOKE IO study to make a difference for individuals who, like you, are managing their cancer with immunotherapy or immuno-oncology (IO) treatment. The study will examine the use of Signatera and the impact it has on treatment decisions for clinical outcomes in cancer patients being treated through immunotherapy. The study will enroll approximately 1700 patients. Natera and its collaborators will collect data on clinical decisions, benefits, and outcomes from enrolled patients for up to two years.

Visit our Signatera BESPOKE IO study page to learn more about joining the study.

Learn More

What is Signatera?

Signatera is a blood test used for cancer detection and surveillance. It is personalized for each patient. A doctor may order Signatera along with routine follow-up exams to determine whether:

There are signs of cancer still in your body
Treatment (e.g., immunotherapy, chemotherapy, radiation) is working
The cancer is likely to come back

How is the Signatera test performed?

A one-time analysis of both blood and tissue determines your unique set of tumor mutations.

The test is custom-built and personalized for you

Signatera detects the presence or absence of cancer each time it is ordered as part of your routine follow-up blood tests.

Understanding your Signatera test results

Your test results will either be positive or negative for the presence of tumor DNA in your blood. Your doctor will receive the test report and will be able to discuss your results and answer questions.

IMPORTANT: Negative results may change over time. A negative Signatera result doesn’t guarantee that tumor DNA is not in your blood, or that it will never be detected in the future. This is why ongoing monitoring with the Signatera test in oncology treatment centers over the course of your cancer care, as directed by your doctor, is recommended—for early detection of residual disease

Negative result

A negative result indicates that tumor DNA was not detected in your blood and that you are more likely to remain cancer-free if you were diagnosed with early stage cancer.
If you have metastatic cancer, a negative result may mean that your treatment was able to decrease the amount of cancer cells to undetectable levels, meaning the treatment has been effective.

Our Tests

Positive result

A positive result indicates that tumor DNA has been detected in your blood and means there is higher risk for your cancer returning if you were diagnosed with early-stage cancer. Your doctor may continue to monitor your ctDNA levels to assess your tumor’s response to treatment.